Search results for "Prospective"

showing 10 items of 3738 documents

Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines a…

2021

Summary Purpose In the ACOSOG Z0011 trial, patients with primary breast cancer and 1–2 tumor-involved sentinel lymph nodes (SLNs) undergoing breast-conserving surgery had no oncological outcome benefit after axillary lymph node dissection (ALND), despite a relevant rate of non-SLN metastases of 27%. According to the St Gallen expert consensus, and NCCN and ASCO clinical guidelines, ALND may be avoided in patients who meet all ACOSOG Z0011 inclusion criteria. This recommendation can also be extended to patients undergoing mastectomy, with 1 or 2 positive SLNs and an indication for chest wall radiation, in whom axillary radiotherapy can be proposed as an alternative to completion ALND. The ai…

AdultCancer Researchmedicine.medical_specialtyLymphovascular invasionmedicine.medical_treatmentSentinel lymph nodeBreast NeoplasmsCohort StudiesBreast cancermedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyMastectomySocieties MedicalAgedAged 80 and overbusiness.industryAxillary Lymph Node DissectionCancerHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseUnited StatesOncologyLymphatic MetastasisAxillaPractice Guidelines as TopicLymph Node ExcisionFemaleGuideline AdherenceRadiologySentinel Lymph NodebusinessMastectomyBulletin du Cancer
researchProduct

A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in c…

1996

To estimate the risk of developing cervical intra-epithelial neoplasia (CIN) among women exposed to human papillomavirus (HPV) type 16, we performed a prospective study in a population-based cohort of more than 15,000 women followed for 34.9 months. Seventy-four women developed CIN during follow-up and were matched for age, time of sampling and area of residence with 148 women who remained CIN-free during follow-up. The blood samples taken at enrollment were tested for serum antibodies to HPV types 16, 18 and 33 capsids. Cervical smears or biopsies were analyzed for the presence of HPV DNA by nested PCR using HPV general primers and by HPV 16- and 18-type-specific PCR. HPV serology and HPV-…

AdultCancer Researchmedicine.medical_specialtyPopulationCervix UteriAntibodies ViralPolymerase Chain ReactionSerologyCohort StudiesRisk FactorsInternal medicineCarcinomamedicineHumansProspective StudiesRisk factorProspective cohort studyeducationPapillomaviridaeSwedenVaginal SmearsGynecologyeducation.field_of_studybusiness.industryPapillomavirus InfectionsAge FactorsAbsolute risk reductionvirus diseasesMiddle AgedUterine Cervical Dysplasiamedicine.diseasefemale genital diseases and pregnancy complicationsTumor Virus InfectionsOncologyDNA ViralCohortFemalebusinessPapanicolaou TestCohort studyInternational Journal of Cancer
researchProduct

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results …

2010

This study evaluated the effects of epoetin alfa on patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy. Early intervention with epoetin alfa was well tolerated and improved anemia-related patient-reported outcomes.

AdultCancer Researchmedicine.medical_specialtySurvivalAnemiaPopulationAntineoplastic AgentsBreast NeoplasmsAcademia–Pharma Intersectlaw.inventionbreast cancer; anemia; erythropoietin; hemoglobin; survival; fatigueHemoglobinsBreast cancerRandomized controlled trialstomatognathic systemlawInternal medicinehemic and lymphatic diseasesBreast CancermedicineClinical endpointHumansBlood TransfusionHemoglobinProspective StudieseducationSurvival rateErythropoietinFatigueAgededucation.field_of_studybusiness.industryEpoetin alfavirus diseasesAnemiaMiddle Agedmedicine.diseasedigestive system diseasesRecombinant ProteinsSurgeryEpoetin AlfaOncologyErythropoietinHematinicsFemalebusinesstherapeuticsmedicine.drug
researchProduct

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

2021

Abstract Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients and methods GAIN-2 was an open-label, randomised, multicentre phase III trial. Two thousand eight hundred and eighty seven patients were randomised 1:1 between three courses each of idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC) versus four cycles of leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by four cycles of tailored and dose-dense docetaxel (dtD) (dtEC-dtD…

AdultCancer Researchmedicine.medical_specialtyTime FactorsAdolescentPaclitaxelCyclophosphamideDose-dense chemotherapymedicine.medical_treatmentBreast NeoplasmsDocetaxelRisk AssessmentDisease-Free SurvivalYoung AdultRisk FactorsAlbuminsGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAdverse effectCyclophosphamideAgedEpirubicinChemotherapybusiness.industryCarcinoma Ductal BreastCancerMiddle AgedInterim analysismedicine.diseaseNeoadjuvant TherapyCarcinoma LobularCarcinoma Intraductal NoninfiltratingOncologyDocetaxelChemotherapy AdjuvantFemalebusinessmedicine.drugEpirubicinEuropean Journal of Cancer
researchProduct

Health-related Quality of Life of Breast Cancer Survivors Attending an Exercise Intervention Study: A Five-year Follow-up

2020

Background/Aim: As the number of breast cancer survivors is increasing, their long-term health-related quality of life (HRQoL) has become an important issue. The aim of the study is to follow up the HRQoL of breast cancer survivors (BCS) in a prospective randomized exercise intervention study and to compare HRQoL to that of the age-matched general female population. Patients and Methods: Following adjuvant treatment, 537 patients aged 35-68 and capable of exercise training were randomized to a 12-month exercise trial. In 182 of those patients, HRQoL was measured by the generic 15D at baseline and followed up for five years. Furthermore, the HRQoL of all BCS answering the 15D at five-year fo…

AdultCancer Researchmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulationBreast NeoplasmsGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifeCancer SurvivorsInternal medicineSurveys and QuestionnairesOutcome Assessment Health CareMedicineHumansProspective StudieseducationDepression (differential diagnoses)AgedPharmacologyeducation.field_of_studyRehabilitationExercise interventionbusiness.industryCancerMiddle Agedmedicine.diseasehumanities3. Good healthExercise TherapyDistress030220 oncology & carcinogenesisQuality of LifeFemalebusinessResearch ArticleFollow-Up Studies
researchProduct

Prospective study on cervical neoplasia IV. Presence of HPV antibodies.

1999

Sera collected in the course of a prospective study carried out in Prague in 1975–1983 were assayed for the presence of human papillomavirus (HPV) antibodies. Women with cervical neoplasia proven by biopsy at enrollment possessed antibodies to peptides derived from E2, E4 and E7 proteins of HPV16 and to virus-like particles (VLPs) of HPV16, -18 and -33 significantly more frequently than matched controls. Women without cervical neoplasia at enrollment who developed the disease in the course of the study differed from matched controls by a higher prevalence of antibodies against VLPs of HPV16 and -18 but not against early antigens of HPV16. In 19 of the latter subjects, paired serum specimens…

AdultCancer Researchmedicine.medical_specialtyvirusesPapillomavirus E7 ProteinsUterine Cervical NeoplasmsAntibodies ViralGastroenterologySerologyAntigenInternal medicineBiopsymedicineHumansProspective StudiesSeroconversionProspective cohort studyPapillomaviridaebiologymedicine.diagnostic_testbusiness.industryvirus diseasesCancerOncogene Proteins ViralMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsDNA-Binding ProteinsOncologyImmunologybiology.proteinFemaleViral diseaseAntibodybusinessBiomarkersInternational journal of cancer
researchProduct

MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing

2000

Beta-blocker therapy results in a functional benefit in patients with heart failure (CHF) due to idiopathic dilated cardiomyopathy (DCM). This study assessed if similar effects were observed in patients with ischemic heart disease (CAD), NYHA II–III after 6 months of therapy with metoprolol. Methods and results: Fifty-two patients with CHF secondary to DCM (26 patients) and CAD (26 patients) and a left ventricular ejection fraction (EF) < 40% were enrolled in the placebo-controlled study. The study medication was titrated over 6 weeks, the mean final dosage was 135 mg/day. Three patients died due to cardiogenic shock, two received placebo and one metoprolol. Eight patients did not complete …

AdultCardiomyopathy DilatedMaleCardiac function curvemedicine.medical_specialtyCardiac VolumeAdrenergic beta-AntagonistsMyocardial IschemiaCardiomyopathyVentricular Function LeftDouble-Blind MethodInternal medicineIdiopathic dilated cardiomyopathyHeart ratemedicineHumansProspective Studiescardiovascular diseasesAgedMetoprololHeart FailureEjection fractionbusiness.industryCardiogenic shockMiddle Agedmedicine.diseaseHeart failureExercise Testcardiovascular systemCardiologyFemaleCardiology and Cardiovascular Medicinebusinesshuman activitiesMetoprololcirculatory and respiratory physiologymedicine.drugEuropean Journal of Heart Failure
researchProduct

Possible misclassification of cardiovascular risk by SCORE in antisynthetase syndrome: results of the pilot multicenter study RI.CAR.D.A

2020

Abstract Objectives To test the ability of an established traditional cardiovascular (CV) risk prediction score [Systematic COronary Risk Evaluation (SCORE)] and its EULAR modified version (mSCORE) to identify antisynthetase syndrome (ASyS) patients at high CV risk and to examine for the first time associations of CV and cerebrovascular surrogate markers with clinical and immunological ASyS parameters. Methods SCORE/mSCORE and the gold standard marker of aortic stiffness [carotid-femoral pulse wave velocity (cfPWV)] were examined in ASyS patients and healthy controls. Moreover, sonography of the common- (CCA) and internal- (ICA) carotid arteries was performed in subsets of both groups, eval…

AdultCarotid Artery DiseasesMaleCarotid atherosclerosismedicine.medical_specialtyPilot ProjectsAntisynthetase syndrome030204 cardiovascular system & hematologyCarotid Intima-Media Thickness03 medical and health sciencesVascular Stiffness0302 clinical medicineRheumatologyInternal medicineDiabetes mellitusHumansMedicinePharmacology (medical)Prospective StudiesPulse wave velocitySubclinical infection030203 arthritis & rheumatologyMyositisbiologybusiness.industryConfoundingGold standard (test)Middle Agedmedicine.diseaseCarotid ArteriesCross-Sectional StudiesHeart Disease Risk FactorsCase-Control Studiescardiovascular systembiology.proteinCardiologyFemaleCreatine kinasebusinessRheumatology
researchProduct

The Randomized Shortened Dental Arch Study

2012

The scientific evidence concerning prosthodontic care for the shortened dental arch (SDA) is sparse. This randomized multicenter study aimed to compare two common treatment options: removable partial dental prostheses (RPDPs) for molar replacement vs. no replacement (SDA). One of the hypotheses was that the follow-up treatment differs between patients with RPDPs and patients with SDAs during the 5-year follow-up period. Two hundred and fifteen patients with complete molar loss in one jaw were included in the study. Molars were either replaced by RPDPs or not replaced according to the SDA concept. A mean number of 4.2 (RPDP) and 2.8 (SDA) treatments for biological or technical reasons occur…

AdultChange over timeMolarmedicine.medical_treatmentDentistryDental Abutmentslaw.inventionTooth LossDental ArchRandomized controlled triallawmedicineDenture Precision AttachmentHumansBicuspidProspective StudiesDenture DesignGeneral DentistryObservation timebusiness.industryJaw Edentulous PartiallyTreatment optionsDenture RetentionMolarDental archTreatment Outcomemedicine.anatomical_structureMulticenter studyDenture Partial RemovableProsthodonticsbusinessFollow-Up StudiesJournal of Dental Research
researchProduct

Rectal Diclofenac administration for prevention of post-Endoscopic Retrograde Cholangio-Pancreatography (ERCP) acute pancreatitis. Randomized prospec…

2019

Introduction. Post-Endoscopic Retrograde Cholangio-Pancreatography pancreatitis (PEP) is a relevant (1-4%) complication of biliopancreatic operative endoscopy. Rectal nonsteroidal anti-inflammatory drugs (specifically, 100 mg of diclofenac) have shown promising prophylactic activity in PEP. The aim of our prospective study is to report whether prophylactic oral versus rectal suppository versus intramuscular diclofenac versus placebo are able to reduce the incidence and the severity of ERCP-induced pancreatitis.Materials and Methods. in this randomized, double-blinded, prospective study, 100 patients (49 male, 51 female), similar with regard to indication for ERCP, were enrolled between Janu…

AdultCholangiopancreatography Endoscopic RetrogradeMalePancreatitiDiclofenacPreventionAnti-Inflammatory Agents Non-SteroidalMiddle AgedERCPTreatment OutcomeDouble-Blind MethodPancreatitisAdministration RectalAcute DiseaseHumansFemaleProspective StudiesComplicationLa Clinica terapeutica
researchProduct